Canopy Growth has lost more than 99% of its value since its 2018 peak, but the company is now healthier with fiscal 2026 revenue up 6% to $200.4 million and cannabis revenue climbing 15%. Canadian medical cannabis revenue hit a record, international sales rebounded, and management targets positive adjusted EBITDA in fiscal 2027. The balance sheet improved to a net cash position of $92 million, yet the company remains unprofitable with negative free cash flow and a history of shareholder dilution. Until consistent profitability is demonstrated, the stock is seen as carrying too many execution risks to be a confident buy.
Canopy Growth CorpRevenue growth and improved balance sheet are positive, but ongoing unprofitability and dilution risks keep outlook uncertain.